Shanghai – An experimental CRISPR-based gene therapy in a first clinical study in boys with duchenne musculoskeletal dystrophy (DMD) partially restored the production of muscle protein dystrophin. However, the effect remained low. One of the 4 boys treated had a severe immune response with fatal outcome...
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
Shanghai – An experimental CRISPR-based gene therapy in a first clinical study in boys with duchenne musculoskeletal dystrophy (DMD) partially restored the production of muscle protein dystrophin. However, the effect remained low. One of the 4 boys treated had a severe immune response with fatal outcome...